Please login to the form below

Not currently logged in
Email:
Password:

Asceneuron appoints chief medical officer

Novartis’ Michael Ryan joins the neurodegenerative diseases specialist

Asceneuron Michael RyanLausanne, Switzerland-based Asceneuron has appointed Michael Ryan as its new chief medical officer.

Ryan brings over 15 years of central nervous system clinical research experience to the role, and takes on responsibility for Asceneuron's pipeline of innovative small molecules and progressing tau modifiers through its clinic.

He joins the neurodegenerative diseases specialist from Novartis, where he had served as vice president of its neuroscience development franchise and therapeutic head for neurodegeneration since 2011.

Prior to this, Ryan was senior director of global research and development at Pfizer, before becoming its senior director of vaccine clinical research and leading the firm's immunotherapy programme in Alzheimer's disease.

He has also held senior clinical positions at MSD Research Laboratories and Wyeth Research in the US.

Dirk Beher, chief executive officer of Asceneuron, said: “We are delighted to welcome Michael to the Asceneuron team.

“His outstanding track record and expertise in neurodegenerative disease are crucial as we are about to progress our first highly brain penetrant and orally bioavailable tau modifier into the clinic for the treatment of a number of orphan CNS disorders.

“We look forward to working with Michael in addressing this high unmet medical need and developing our pipeline to bring our innovative small-molecule therapeutics to patients.”

19th December 2016

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
CSafe Global

CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...

Latest intelligence

Five companies 20 for 2020
20 for 2020 – Five pharma companies to watch
As a new decade gets into gear, we take a look at five pharma companies that have a lot riding on 2020...
The growing clinical importance of patient-reported outcomes (PROs)
Traditionally, the success or otherwise of medical treatments has been assessed by mortality or clinical assessments of health. However, patient self-reports of health are increasingly seen as central to the...
Generation Z
The roaring ‘20s and Generation Z
How a new generation will shape pharma comms this decade...

Infographics